Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Treatment crawled date : 2021 - 05 - 06 save search
Worldwide Tertiary Water and Wastewater Treatment Technologies Industry to 2027 - by Type, Application and Geography
Published: 2021-05-06 (Crawled : 17:00) - prnewswire.com
DD | News | $73.8 -0.15% 0.0% 1.5M
|
Process Industries
|
| O: 0.06%
H: 0.65%
C: 0.53%
MMM | $93.0 0.41% -0.4% 3.7M
|
Producer Manufacturing
|
| O: -0.08%
H: 0.61%
C: 0.56%
treatment application
Abbott Seeks Better Treatment Options for Patients with Both Atrial Fibrillation and Heart Failure with New Trial
Published: 2021-05-06 (Crawled : 14:00) - biospace.com/
ABT | News | $107.59 0.49% -0.09% 3.8M
|
Health Technology
|
| O: -0.39%
H: 0.7%
C: 0.63%
treatment heart trial
GE Healthcare Acquires Zionexa; Molecular Imaging Agent Aims to Enable More Targeted Treatment for Metastatic Breast Cancer Patients
Published: 2021-05-06 (Crawled : 14:00) - biospace.com/
GE | News | $162.62 8.28% 0.22% 19M
|
Electronic Technology
|
| O: 0.08%
H: 0.68%
C: -0.08%
treatment molecular cancer breast cancer imaging metastatic breast cancer
BIOSt® Nematicide Seed Treatment Reduces Greenhouse Gas Emissions in Soybeans and Corn by 85%+ Compared to Conventional Pesticides
Published: 2021-05-06 (Crawled : 13:00) - globenewswire.com
MBII | $0.7981 -20.19% 1.49%
|
Process Industries
|
| O: -0.6%
H: 2.4%
C: 1.2%
treatment pest
Aeterna Zentaris Announces the Selection of a Development Candidate in the DC-PTH Program for the Potential Treatment of Primary Hypoparathyroidism
Published: 2021-05-06 (Crawled : 12:15) - globenewswire.com
AEZS | $1.97 0.73% 6K
|
Health Technology
|
| O: -0.74%
H: 0.0%
C: -0.16%
treatment potential
Hepion Pharmaceuticals Completes Final Patient Recruitment in Phase 2a 'AMBITION' Clinical Trial of CRV431 for the Treatment of Advanced NASH
Published: 2021-05-06 (Crawled : 12:00) - globenewswire.com
HEPA | $1.47 4.26% 4.08% 71K
|
Health Technology
|
| O: -1.23%
H: 1.86%
C: 0.62%
treatment phase 2 nash trial phase 2b crv431
Invizius Announces Successful Series A Financing to Develop Anti-Inflammatory Treatment for Haemodialysis
Published: 2021-05-06 (Crawled : 08:00) - prnewswire.com
ABCM | News | $23.99 0.0% 7.4M
|
Health Technology
|
| O: -1.62%
H: 1.31%
C: 0.68%
treatment
Antengene Announces Selinexor Added to Multiple Treatment Regimens in 2021 CSCO Guidelines
Published: 2021-05-06 (Crawled : 04:00) - prnewswire.com
KPTI | $1.085 -3.98% -4.15% 1.6M
|
Health Technology
|
| O: 0.37%
H: 1.11%
C: 0.0%
treatment
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Combined With Trastuzumab and Chemotherapy as First-line Treatment in Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma
Published: 2021-05-05 (Crawled : 01:00) - biospace.com/
MRK | $126.88 -0.05% -0.13% 7.5M
|
Health Technology
|
| O: 0.14%
H: 2.14%
C: 2.1%
treatment fda positive therapy fda approval her2+ keytruda her2- her2
MediciNova Receives a Notice of Intention to Grant for a New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Europe
Published: 2021-05-06 (Crawled : 01:00) - globenewswire.com
MNOV | $1.34 -3.73% 9.3K
|
Health Technology
|
| O: 2.35%
H: 0.23%
C: -8.05%
treatment europe sclerosis patent als mn-166 riluzole
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.